Petranova, T.
Boyanov, M.
Shinkov, A.
Petkova, R.
Intorcia, M.
Psachoulia, E.
Funding for this research was provided by:
Amgen (Europe) GmbH
Article History
Received: 24 July 2017
Accepted: 14 December 2017
First Online: 21 December 2017
Compliance with ethical standards
: The study protocol was approved by a central regulatory ethics committee, in accordance with the ethical principles of the Declaration of Helsinki.
: TP has received speaker fees from MSD, Novartis, Roche, Amgen, Elly Lilly, Pfizer and honoraria for advisory board meetings from Amgen and Elly Lilly. MB has received speaker fees from MSD, Novartis, Roche, Amgen, Merck and Aventis, and honoraria for advisory board meetings from Amgen and MSD. AS have no conflicts of interest to disclose. RP and MI are employees and shareholders of Amgen. EP is an employee of Biogen International and holds stock. She was an employee of Amgen at the time the study was conducted and when the manuscript was being prepared.